Kastia

Rosuvastatin, the active ingredient in Kastia, is a HMG‑CoA reductase inhibitor presented as an oral dosage form for oral use. It lowers elevated cholesterol levels and is used to reduce the risk of cardiovascular events in adult patients with hypercholesterolemia.

GNH USA supplies Kastia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent product quality across global markets. The company adheres to stringent quality standards and offers comprehensive logistics solutions for timely delivery.

Rosuvastatin is indicated for lipid disorders and cardiovascular risk reduction. - Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Primary prevention of cardiovascular disease: lowers the risk of heart attack and stroke in patients without established disease. - Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with prior myocardial infarction or stroke.

Rosuvastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Muscle pain: aching or soreness in limbs. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with potential kidney injury. - Elevated liver enzymes: indicating possible hepatic injury. - Severe allergic reaction: including rash, swelling, or anaphylaxis.

When prescribing rosuvastatin, several safety considerations should be observed. - Liver function monitoring: assess baseline transaminases and repeat periodically. - Renal function assessment: adjust use in patients with severe renal impairment. - Muscle symptom evaluation: discontinue if unexplained muscle pain, tenderness or weakness occurs. - Pregnancy contraindication: avoid use in pregnancy due to fetal risk (Category X). - Concomitant drug review: check for interactions with CYP2C9 inhibitors and other lipid‑lowering agents. - Store at room temperature: keep in the original container, protect from moisture and light.

Rosuvastatin interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Gemfibrozil: markedly increases rosuvastatin exposure and risk of myopathy. - Strong CYP2C9 inhibitors (e.g., azole antifungals): raise rosuvastatin levels. - High‑dose niacin: enhances risk of muscle toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Digoxin: increased serum digoxin concentrations have been reported. - Other statins: combined therapy can increase risk of adverse muscle events.